Search Results
Your search for ,USE matches 11257 pages
Showing 2301 - 2350New Interactive Map of Oncology Puts COVID-19, Equity Data Into Perspective
In an effort to highlight cancer care inequities during the COVID-19 pandemic, ASCO has launched the Interactive Map of Oncology, a data visualization tool that allows users to explore geographic distribution of systemic and socioeconomic factors that influence cancer care delivery in the United...
New FDA-Approved Oncology Drugs (2021–2022)
Over the past year (May 2021–May 2022), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers and adverse events. The new approvals and accelerated approvals are listed below. FAM-TRASTUZUMAB...
An International Leader Bridges the Political Divide in the Name of Humanity and Cancer Care
Michael Silbermann, DMD, PhD, was born on January 19, 1935, in the old quarter of Acre, a northern Arab city stretching along the north end of the Bay of Haifa in present-day Israel. “Acre, which was developed more than 4,000 years ago, was one of the primary harbors of the Phoenician people....
NCI Launches Program to Offer Molecular Characterization of Childhood Cancers
In support of President Biden’s Cancer Moonshot goal of fostering data sharing in cancer research, the National Cancer Institute (NCI), which is part of the National Institutes of Health, has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor...
Growing Up in a House Filled With Science Leads to a Career in Breast Cancer and Health Outcomes Research
Debra Patt, MD, PhD, MBA, Executive Vice President of Policy and Strategic Initiatives for Texas Oncology, was reared in Plano, Texas, a city in the sprawling Dallas–Fort Worth metroplex. “My father was an electrical engineer with a PhD, and all throughout my childhood, I was exposed to the wonders ...
A Community Practitioner and Policy Advocate Who Stresses Holistic, Patient-Centered Care
Community practices have long been a keystone of our nation’s oncology care delivery system by allowing patients with cancer to receive specialized treatment near their homes and places of business. Innovative clinicians in the community setting are also leading efforts to create a more efficient...
Sunil Verma, MD, Navigates an International Path From Clinical Educator in Oncology to Leadership in Industry
In this installment of The ASCO Post’s Living a Full Life series, guest editor, Jame Abraham, MD, spoke with Sunil Verma, MD, the Global Head of Oncology, Medical, at AstraZeneca. Sunil Verma, MD, was born in Zambia, a landlocked country at the crossroads of Central, Southern, and East Africa. “My...
Missed Opportunities in Geriatric Oncology Research
The underrepresentation of older patients (≥ 65 years) in clinical trials has been well documented for more than 20 years. This has been an issue at all phases of drug development, including pivotal trials for drug approvals,1 despite the fact that many of these new therapeutics will primarily be...
From the Segregated Tennis Courts of Washington, DC, to a Leadership Role in Surgical Oncology
Success in tennis demands precision timing, extraordinary hand-eye dexterity, and commanding mental and physical vigor. According to Harold P. Freeman, MD, the discipline and skills he learned on the tennis courts at an early age stood him in good stead during his remarkable life’s journey. “My...
A Leader in Oncology Balances Philosophy, Medicine, and Humility
"The reality is that closure is a myth. My personal and professional experience with those who have lost friends and family, including children, has taught me that going on with life is not the same as gaining closure. The wound of loss is a part of each person’s life forever,” wrote...
A Son Forges a Noted Career in Oncology Rather Than Follow in His Father’s Illustrious Footsteps in Dermatology
Rakesh Chopra, MD, former Chairman and Head of the Oncology Department of Artemis Hospitals, was born in New Delhi, the capital of modern India. As a child, he attended the Lawrence School, Sanawar, a private boarding school in Himachal Pradesh, among beautiful sylvan surroundings. “Sanawar was...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. “This year’s Special...
After Rounds on the Leukemia Ward, a Young Doctor Finds His Calling in Stem Cell Transplantation
Internationally recognized stem cell transplant pioneer Richard E. Champlin, MD, was born in Milwaukee and moved to Homewood, a suburb on the southern lip of Chicago, with his parents when he was 3 years old. Following high school, Dr. Champlin entered Purdue University in Indiana to pursue a...
Multiple Myeloma: Treatment Conundrums
The availability of numerous new agents for treating multiple myeloma has created some “conundrums” for clinicians, said Sergio Giralt, MD, Deputy Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center and the Melvin Berlin Family Chair in Myeloma Research and...
Use of Telemedicine for Cancer Care Increased During the COVID-19 Pandemic but Varied by Race, Socioeconomic Status, and Other Factors
With the rapid acceleration of the spread of the COVID-19 virus in the United States in March 2020, telemedicine visits became more common for cancer care. However, in an evaluation of telemedicine inequities among patients with 21 common cancers, there were distinctly lower levels of telemedicine...
FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AML
On May 25, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo) in combination with azacitidine for patients with newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test in adults aged 75 or older, or who have...
New England Cancer Specialists to Become Affiliate Member of Dana-Farber Cancer Institute
New England Cancer Specialists has recently become an Affiliate Member of the Dana-Farber Cancer Institute. Affiliate Membership reflects a demonstrated commitment to excellence by meeting a wide array of standards and best practices in oncology care. Although New England Cancer Specialists is the...
ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage Triple-Negative Breast Cancer
A rapid update to the ASCO Guideline on neoadjuvant therapy for breast cancer adds a recommendation on the use of pembrolizumab in patients with high-risk early-stage triple-negative breast cancer.1 The update follows a recent analysis from the randomized phase III KEYNOTE-522 trial that showed a...
An Emergency Room Physician Offers Hands-on Perspective for Treating Patients With Cancer
According to research in the literature, adults with cancer generate high rates of emergency department visits, leading to hospitalization roughly 60% of the time—nearly four times the rate of the general population. Although many of these visits could be prevented, this phenomenon offers numerable ...
A Second Edition Adds New Value to Personalized Medicine
Since the publication of the first draft of the human genome, genotyping and genomics have been integrated into standard clinical care for select cancers. But as precision medicine in oncology develops to comprise big data, proteomics, transcriptomics, molecular imaging, and more, there are...
PD-1 Inhibition in First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: More to Come on New Paradigm
Esophageal cancer is associated with significant morbidity and mortality worldwide, with more than 600,000 new cases and 540,000 deaths in 2020. The squamous cell histology comprises nearly 90% of cases globally, despite its steady decline in the United States over the past 40 years. Historically,...
Understanding Oncologists’ Perceptions About Palliative Care and the Barriers Preventing Its Use
Despite studies showing the benefits of early palliative care in improving the quality of life of patients with advanced cancer (including reducing symptoms of depression),1 a recent survey of oncologists found there is broad variation in the appropriate utilization of this care.2 Conducted by...
Tackling the Global Burden of Cancer on Adolescents and Young Adults With Cancer
Several recent studies examining the global burden of cancer on adolescents and young adults (AYAs) show the growing magnitude of the disease’s impact on the lives of individuals between the ages of 15 and 39. Although considered a rare occurrence, cancer in this age group has risen by...
Pembrolizumab for MSI-H/dMMR Advanced Endometrial Carcinoma
On March 21, 2022, pembrolizumab was approved for patients with advanced endometrial carcinoma that is microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR), as determined by a U.S. Food and Drug Administration (FDA)-approved test, who have disease progression following prior...
Steven A. Rosenberg, MD, PhD, Recognized With 2022 Pezcoller Foundation–AACR International Award
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research was presented to Steven A. Rosenberg, MD, PhD, at the Association’s 2022 Annual Meeting, held in New Orleans. Dr. Rosenberg was honored for his discovery and ...
Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
On April 1, 2022, axicabtagene ciloleucel was approved for adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.1 It is not indicated for the treatment of patients with primary central nervous system...
How St. Jude and the WHO Are Sparking an International Movement to Increase Treatment Access for Children With Cancer
The toll of cancer on children, especially those living in low-resource countries, is staggering. Each year, an estimated 400,000 children and adolescents worldwide develop cancer,1 and despite improved survival rates, the global 5-year net childhood cancer survival rate is only 37.4%,2 making...
Novel Neoadjuvant Therapy May Boost Response in Resectable NSCLC
Use of multiple immune pathway inhibitors appears to be superior to checkpoint inhibitor therapy alone as neoadjuvant therapy for resectable non–small cell lung cancer (NSCLC), according to the results of the phase II NeoCOAST trial presented at the American Association for Cancer Research (AACR)...
Combination Therapy of Olaparib, Cyclophosphamide, and Metformin Under Study in Advanced Endometrial Cancer
A triplet regimen consisting of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib, metronomic (the chronic administration of low, equally spaced doses of) cyclophosphamide, and metformin demonstrated activity in elderly, heavily pretreated patients with recurrent, advanced endometrial...
Gabapentin May Be an Effective Alternative to Opioids for Patients With Head and Neck Cancer Receiving Radiation
Patients with head and neck cancer undergoing radiation therapy may be less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, findings from a team of radiation oncologists showed. Their report, published by Ma et al in JAMA ...
Does Treatment With 5α-Reductase Inhibitors Impact the Risk of Dying of Prostate Cancer Among Men Without a Prior Diagnosis of the Disease?
In a Swedish study reported in JAMA Oncology, Björnebo et al found that longer use of 5α-reductase inhibitors (5-ARIs) for the treatment of benign prostatic hyperplasia was associated with a reduced risk of prostate cancer mortality among men without a prior diagnosis of prostate cancer. As stated...
Mario Sznol, MD, and Stefania Scala, MD, on Improving Responses to Immunotherapy in Patients With Melanoma
Invited study discussant of the use of ipilimumab plus nivolumab in resistant melanoma, at the AACR Annual Meeting 2022, Mario Sznol, MD, of Yale University Cancer Center, indicated that the substantial increase in progression-free survival at 6 months was not maintained. “The durable...
Approaches to Potentiate Immune Response in Patients Who Do Not Respond to Anti–PD-1 Therapy for Melanoma
A sizable proportion of patients with advanced melanoma will experience disease progression on anti–PD-1 therapy, and the optimal treatment of such patients represents an unmet need. Two studies presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 explored separate...
Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical Trials
Two oncologists who are now heads of oncology development for pharmaceutical companies discussed the future of cancer drugs at the Community Oncology Alliance’s 2022 Community Oncology Conference. They were Johanna Bendell, MD, Global Head of Oncology, Pharma Research, and Early Development at...
Researchers Develop and Monitor Approaches to Fix Blood Vessel Abnormalities That Make Tumors Difficult to Treat
Tumors send out signals that impair normal blood flow, which makes them hard to treat with multiple therapies, including radiation, chemotherapy, targeted therapies, and immunotherapy. Impaired blood supply creates an environment low in oxygen levels, which causes the tumors to take on aggressive...
Intraoperative Margin Assessment in Breast-Conserving Surgery Using a Pegulicianine Fluorescence–Guided System
In the INSITE study reported in JAMA Surgery, E. Shelley Hwang, MD, MPH, and colleagues found that use of an intraoperative imaging agent with a pegulicianine fluorescence–guided system (pFGS) was effective in detecting residual cancer in the tumor bed of women with breast cancer undergoing...
NCCN Clinical Practice Guidelines in Oncology: 2022 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...
The Future of Community Oncology Practice
Although community oncology practice may have been changing before the COVID-19 pandemic, it amplified industry trends. At the 2022 Community Oncology Alliance’s Community Oncology Conference, a panel of experts discussed issues related to the future of community cancer care, including...
Do Electronic Health Interventions Improve Quality of Life and Other Health Outcomes in Patients With Breast Cancer?
In a systematic review and meta-analysis reported in the Journal of Clinical Oncology, Singleton et al found that electronic health interventions were associated with improved quality of life, distress, self-efficacy, and fatigue vs usual care during or after treatment in patients with breast...
CoVac-1 Vaccination Studied for Prevention of Severe COVID-19 in Immune-Deficient Patients With Cancer
CoVac-1, a multipeptide COVID-19 vaccine candidate, elicited immunogenicity in patients with cancer and disease-related or treatment-related immunoglobulin deficiency in a phase I/II trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 These patients are...
Colonoscopy After Positive FIT Test May Reduce Risk of Death From Colorectal Cancer
Recent research underlines the importance of following up with a colonoscopy exam after a positive result on an at-home stool test to screen for colorectal cancer. The test, known as the fecal immunochemical test (FIT), checks for traces of blood in patient-collected stool samples, which can be an...
Report Finds Uptake of Erdafitinib for Urothelial Cancer May Be Limited, Despite Positive Real-World Survival Data
The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a report published as a research letter by Nimgaonkar et al in JAMA Oncology. Researchers analyzed a large, nationwide database of cancer...
Next-Generation PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors
The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305 suggests this drug may be a welcome advance over its U.S. Food and Drug Administration (FDA)-approved predecessors in the treatment of solid tumors with alterations in...
Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer
The use of a polygenic score incorporating variations in prostate-specific antigen (PSA) values that are not due to cancer may allow for more precise PSA screening, according to findings of a large genome-wide association study presented at the American Association for Cancer Research (AACR) Annual ...
New Research Encourages Harnessing Health Technology to Help Patients With Cancer Quit Smoking
New research published by Ramsey et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that the inclusion of the smoking cessation tool Electronic Health Record–Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) into electronic health records may increase...
Anti–CTLA-4 Antibody–Based Treatment in Patients With Metastatic Melanoma Experiencing Disease Progression on Relatlimab/Nivolumab
In a study reported as a letter to the editor in The New England Journal of Medicine, Alexander M. Menzies, MD, and colleagues found that patients with metastatic melanoma who had progressive disease while receiving relatlimab/nivolumab had poor responses to anti–CTLA-4–based treatment. As noted...
Rehospitalization and Emergency Department Visits After CAR T-Cell Therapy in Commercially Insured Patients With Cancer
In a single-institution study reported in a research letter in JAMA Oncology, Kenzik et al found substantial rates of rehospitalization and emergency department visits after chimeric antigen receptor (CAR) T-cell therapy among commercially insured patients with cancer. Study Details The study...
Beyond Immunotherapy: New Targeted Agents for Advanced NSCLC
The advent of PD-1 and PD-L1 checkpoint inhibitors has changed the treatment landscape of advanced non–small cell lung cancer (NSCLC), but only approximately 20% of patients treated with immunotherapy will be alive at 5 years. According to Melissa L. Johnson, MD, Director, Lung Cancer Research,...
ASTRO Issues Clinical Guideline on Radiation Therapy for Brain Metastases
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases. Evidence-based recommendations guide the multidisciplinary planning and delivery of advanced radiation therapy techniques to...
Short and Shorter Screening Tools for Food Insecurity
A survey of oncology registered dietitian nutritionists (RDNs)1 found that most of those surveyed were not using a validated assessment tool to identify food insecurity but expressed interest in obtaining the Six-Item Short Form of the Food Security Survey Module.2 The six-item food insecurity...
